Dikla Atias

Dikla Atias

Auto-generated profile, based on publicly available information

Dikla Atias

Pancreatic Cancer Translational Research Laboratory, Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
BABenjamin Assouline
Benjamin Assouline
RKRachel Kahn
Rachel Kahn
LHLutfi Hodali
Lutfi Hodali
RCReba Condiotti
Reba Condiotti
YEYarden Engel
Yarden Engel
IBIttai Ben-Porath
Ittai Ben-Porath
Senescent cells within tumors and their stroma exert complex pro- and anti-tumorigenic functions. However, the identities and traits of these cells, and the potential for improving cancer therapy through their targeting, remain poorly characterized. Here, we identify a senescent subset within previously-defined cancer-associated fibroblasts (CAFs) in pancreatic ductal adenocarcinomas (PDAC) and in premalignant lesions in mice and humans. Senescent CAFs isolated from mouse and humans expressed elevated levels of immune-regulatory genes. Depletion of senescent CAFs, either genetically or using the Bcl-2 inhibitor ABT-199 (venetoclax), increased the proportion of activated CD8+ T cells in mouse pancreatic carcinomas, whereas induction of CAF senescence had the opposite effect. Combining ABT-199 with an immune checkpoint therapy regimen significantly reduced mouse tumor burden. These results indicate that senescent CAFs in PDAC stroma limit the numbers of activated cytotoxic CD8+ T cells, and suggest that their targeted elimination through senolytic treatment may enhance immunotherapy.

14 July 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
CSChani Stossel
Chani Stossel
MRMaria Raitses-Gurevich
Maria Raitses-Gurevich
DADikla Atias
Dikla Atias
TBTamar Beller
Tamar Beller
YGYulia Glick Gorman
Yulia Glick Gorman
TGTalia Golan
Talia Golan
Germline BRCA–associated pancreatic ductal adenocarcinoma (glBRCA PDAC) tumors are susceptible to platinum and PARP inhibition. The clinical outcomes of 125 patients with glBRCA PDAC were stratified based on the spectrum of response to platinum/PARP inhibition: (i) refractory [overall survival (OS) <6 months], (ii) durable response followed by acquired resistance (OS 36 months). Patient-derived xenografts (PDX) were generated from 25 patients with glBRCA PDAC at different clinical time points. Response to platinum/PARP inhibition in vivo and ex vivo culture (EVOC) correlated with clinical response. We deciphered the mechanisms of resistance in glBRCA PDAC and identified homologous recombination (HR) proficiency and secondary mutations restoring partial functionality as the most dominant resistant mechanism. Yet, a subset of HR-deficient (HRD) patients demonstrated clinical resistance. Their tumors displayed basal-like molecular subtype and were more aneuploid. Tumor mutational burden was high in HRD PDAC and significantly higher in tumors with secondary mutations. Anti–PD-1 attenuated tumor growth in a novel humanized glBRCA PDAC PDX model. This work demonstrates the utility of preclinical models, including EVOC, to predict the response of glBRCA PDAC to treatment, which has the potential to inform time-sensitive medical decisions. Significance: glBRCA PDAC has a favorable response to platinum/PARP inhibition. However, most patients develop resistance. Additional treatment options for this unique subpopulation are needed. We generated model systems in PDXs and an ex vivo system (EVOC) that faithfully recapitulate these specific clinical scenarios as a platform to investigate the mechanisms of resistance for further drug development. This article is highlighted in the In This Issue feature, p. 1749

1 September 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
AJAditi Jain
Aditi Jain
LALebaron C. Agostini
Lebaron C. Agostini
GMGrace A. McCarthy
Grace A. McCarthy
SCSaswati N. Chand
Saswati N. Chand
ARAnnJosette Ramirez
AnnJosette Ramirez
JBJonathan Brody
Jonathan Brody
Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) have an average survival of less than 1 year, underscoring the importance of evaluating novel targets with matched targeted agents. We recently identified that poly (ADP) ribose glycohydrolase (PARG) is a strong candidate target due to its dependence on the pro-oncogenic mRNA stability factor HuR (ELAVL1). Here, we evaluated PARG as a target in PDAC models using both genetic silencing of PARG and established small-molecule PARG inhibitors (PARGi), PDDX-01/04. Homologous repair–deficient cells compared with homologous repair–proficient cells were more sensitive to PARGi in vitro. In vivo, silencing of PARG significantly decreased tumor growth. PARGi synergized with DNA-damaging agents (i.e., oxaliplatin and 5-fluorouracil), but not with PARPi therapy. Mechanistically, combined PARGi and oxaliplatin treatment led to persistence of detrimental PARylation, increased expression of cleaved caspase-3, and increased γH2AX foci. In summary, these data validate PARG as a relevant target in PDAC and establish current therapies that synergize with PARGi. Significance: PARG is a potential target in pancreatic cancer as a single-agent anticancer therapy or in combination with current standard of care.

15 February 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
LVLeonid Visochek
Leonid Visochek
ACAsher Castiel
Asher Castiel
LMLeonid Mittelman
Leonid Mittelman
MEMichael Elkin
Michael Elkin
DADikla Atias
Dikla Atias
Malka Cohen-ArmonMalka Cohen-Armon
Malka Cohen-Armon
Exclusive destruction of mitotic spindles in human cancer cells

22 October 2019 in Oncotarget
Verified
Journal Article
Open access
PDF file
LVLeonid Visochek
Leonid Visochek
DADikla Atias
Dikla Atias
ISItay Spektor
Itay Spektor
ACAsher Castiel
Asher Castiel
TGTalia Golan
Talia Golan
Malka Cohen-ArmonMalka Cohen-Armon
Malka Cohen-Armon
Oncotarget | https://doi.org/10.18632/oncotarget.27268 Leonid Visochek, Dikla Atias, Itay Spektor, Asher Castiel, Talia Golan, Malka Cohen-Armon